Cited by 260Inflammatory Bowel DiseaseHealth Systems, Economic Evaluations, Quality of LifeStatistical Methods in Clinical Trials

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

Williet, Nicolas, Sandborn, William J., Peyrin–Biroulet, Laurent·2014·Clinical Gastroenterology and Hepatology

DOI 10.1016/j.cgh.2014.02.016

Open this paper in CoChat — free account

Abstract

The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life, disability, or fatigue. Several disease-specific scales have been developed to assess these PROs and commonly are used in clinical trials. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life, measured by the Short-Form 36 questionnaire or disease-specific scales such as the Inflammatory Bowel Disease Questionnaire or its shorter version. Recently considered factors include fatigue, depression and anxiety, and work productivity, as measured by the Functional Assessment Chronic Illness Therapy-Fatigue, the Hospital Anxiety Depression, and the Work Productivity Activity Impairment Questionnaire, respectively. However, few data are available on how treatment affects these factors in patients with IBD. Although disability generally is recognized in patients with IBD, it is not measured. The international IBD disability index currently is being validated. None of the PROs currently used in IBD were developed according to FDA guidance for PRO development. PROs will be a major primary end point of future trials. FDA guidance is needed to develop additional PROs for IBD that can be incorporated into trials, to better compare patients' experience with different therapies.

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2014.02.016

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Untitled work
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Untitled work
(1970) · Cited by 24,983
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
The Fatigue Severity Scale: Application to Patients With Multiple Sclerosis and Systemic Lupus Erythematosus
Krupp, L. B. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460115022 · Cited by 6,172
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P. W., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,404
The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue
Smets, E. M. A., Garssen, B., Bonke, B., & de Haes, J. C. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)00125-o · Cited by 3,622
Development and validation of the State Hope Scale.
Snyder, C. R. R., Sympson, S. C., Ybasco, F. C., Borders, T. F., Babyak, M. A., & Higgins, R. L. (1996) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.70.2.321 · Cited by 3,584

Flagged first, then by citations

Show all 150 references

Research works printed but not linked: 2

Piper, 1990, Piper fatigue scale available for clinical testing, Oncol Nurs Forum, 17, 661
Masachs, 2007, [Spanish translation, adaptation, and validation of the 32-item questionnaire on quality of life for inflammatory bowel disease(IBDQ-32)], Rev Esp Enferm Dig, 99, 511

Sorted by citations

Items 201–260 of 260

Mindfulness Practice Is Associated With Subjective Wellbeing Homeostasis Resilience in People With Crohn's Disease but Not Ulcerative Colitis
Lyall, K., Beswick, L., Evans, S., Cummins, R. A., & Mikocka‐Walus, A. A. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.797701 · Cited by 2
“Patient reports are becoming important outcome measures for clinical research (64), however, some studies have found subjective measures of patient functioning do not always correlate with objective measures of disease activity (65, 66).”
Background
Responsiveness and clinical utility of PROMIS instruments in pediatric Crohn's disease: insights from a longitudinal study
Azevedo, S., Oliveira, M. M., Nogueira, P., & Lopes, A. I. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1473286 · Cited by 2
Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial
Miranda-Cordero, R. M., Bosques‐Padilla, F., Martinez-Vazquez, M. A., Barajas-Maldonado, C., Rodríguez-Mendoza, M. M., & Yamamoto-Furusho, J. K. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251318032 · Cited by 2
Iron deficiency should not be accepted in patients with inflammatory bowel disease – a Scandinavian expert opinion
Detlie, T. E., Burisch, J. M., Jahnsen, J., Bonderup, O. K., Hellström, P. M., Lindgren, S. C., & Frigstad, S. O. (2025) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2487907 · Cited by 2
“…inflammation with the use of anti-inflammatory treatment. the underlying target is to improve patients’ quality of life and reduce complications [38,52]. to achieve this, optimised iron dosing is important. it has been shown that high doses of iron reduce the probability of needing another…”
Predictors of health-related quality of life in patients with Crohn’s disease receiving biological therapy
Lundquist, L. R., Rasmussen, B., Waldorff, F. B., Wehberg, S., Kjeldsen, J., & Haastrup, P. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1974086 · Cited by 2
“The Food and Drug Administration and European Medicines Agency are also moving away from clinical indices as clinical trial endpoints, and criteria have been set for the development and implementation of these in clinical trials and clinical practice [21,31,32].”
Background
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis
Wong, E. C. L., Hasan, B., Dulai, P. S., Marshall, J. K., Reinisch, W., & Narula, N. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2105169 · Cited by 2
“The US FDA now mandates that IBD clinical trials include PRO-based endpoints [21,22].”
Background
Health‐related Quality of Life in a Prospective Study of Ultrasound to Detect Cystic Fibrosis–related Liver Disease in Children
Schwarzenberg, S. J., Palermo, J. J., Ye, W., Huang, S., Magee, J. C., Alazraki, A. L., Freeman, A. J., Harned, R. K., Karmazyn, B. W., Karnsakul, W. W., et al. (2022) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003605 · Cited by 2
“symptom profile, measurement of HRQoL may give providers crucial information needed to appropriately modify care plans (3,4).”
Background
To STRIDE or not to STRIDE: a critique of “treat to target” in ulcerative colitis
Herrlinger, K. R., & Stange, E. F. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2397654 · Cited by 2
“…including absence of disability and quality of life [21]), mentioned in STRIDE II as long-term targets, as well as depression, anxiety, fatigue, and work productivity or other clinical indices like the Simple Clinical Colitis Activity Index (SSCCI) [22] may become more relevant in the future [23].”
Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms
Dulai, P. S., & Peyrin‐Biroulet, L. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.060 · Cited by 2
Translation, cross-cultural adaptation and validation of the Chinese version of the IBD-Control questionnaire: A patient-reported outcome measure in inflammatory bowel disease
Guo, B., Li, H., Cui, Q., Li, J., Yu, Y., Li, Z., & Wang, J.-W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311529 · Cited by 1
“Furthermore, the validated Chinese version of the IBD-Control questionnaire would enable Chinese IBD patients to actively participate in the management of their disease, potentially improving treat-ment adherence and outcomes [18].”
Evaluation of the adherence of patients with chronic inflammatory bowel diseases to a PRO telemonitoring using connected devices: a prospective monocentric study
Delhougne, N., Monin, L., Vieujean, S., Kemseke, C. V., Reenaers, C., Warling, O., & Louis, E. (2024) · Acta gastro-enterologica belgica · doi:10.51821/87.4.13449 · Cited by 1
Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior?
Gracie, D. J., & Ford, A. C. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.93 · Cited by 1
Recent advances in the endoscopic assessment of ulcerative colitis
Iacucci, M., & Panaccione, R. (2016) · Techniques in Gastrointestinal Endoscopy · doi:10.1016/j.tgie.2016.08.006 · Cited by 1
Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis
Ma, X., Xu, H., & Zhang, D. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-055182 · Cited by 1
The Short Health Scale: A Valid and Reliable Quality-of-Life Scale for Mainland Chinese Patients with Inflammatory Bowel Disease
Hou, J., Peng, B., Zhang, S.-J., Luo, Y., Chen, Y., Cai, J., Wen, Y., Mi, H., Luo, J., Zheng, X.-M., et al. (2022) · Palliative Medicine Reports · doi:10.1089/pmr.2021.0066 · Cited by 1
“Health-related quality of life (HRQoL) has been widely used to assess clinical treatment outcomes in patients with IBD in recent years.(6,7) HRQoL is a broad, multidimensional concept, covering aspects related to patient perception, experience, daily function, and so on.”
Method
Understanding diagnostic delays and health outcomes for inflammatory bowel disease: a mixed-methods study of patients’ perspectives
Purc‐Stephenson, R. J., & Blake, K. (2024) · Quality of Life Research · doi:10.1007/s11136-024-03852-4 · Cited by 2
“The use of PROMs in IBD research to assess quality of life beyond clinical indices has increased [31–33].”
IBD-related disability among patients with ulcerative colitis in China: a cross-sectional study
Zhang, M., Liu, X., Min, S., Shen, H., & Zhu, L. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251333989 · Cited by 1
“30,31 A meta-analysis demonstrated a significantly higher prevalence of psychiatric comorbidities in IBD patients compared to the general population, including depression (OR (95% CI) = 1.42 (1.33–1.52), p 0.0001), anxiety (OR (95% CI) = 1.3 (1.22– 1.44), p 0.0001), and bipolar disorder (OR…”
Influential
Clinical outcome assessment may be a more useful tool for supporting inflammatory bowel disease clinical practice than just patient-reported outcome measures
Kamat, N., Patil, G. K., Dalal, A., & Maydeo, A. P. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2536610 · Cited by 1
Editorial: post hoc analysis of SONIC trial
Fraser, A. G. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13179 · Cited by 1
“It may prove to be more appropriate, as recommended recently by the FDA, to consider patient-related outcomes (such as IBDQ) separately from biological outcomes.(7)”
Background
Editorial: untangling symptoms from mucosal healing in UC – a note of caution for patient‐reported outcomes
Bryant, R. V., Costello, S. P., & Andrews, J. M. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13416 · Cited by 1
“importance now is that the Food and Drug Administration (FDA) is moving towards composite trial endpoints for drug development, incorporating both PRO’s and endoscopic activity.(5) This approach has risks, as there is the potential to impair interpretation of the efficacy of”
Background
Inflammatory bowel disease and complementary and alternative medicine - The perspectives of patients and healthcare professionals
Lindberg, A. (2015) · Figshare · Cited by 1
Characterisation of 3000 patient reported outcomes with predictive machine learning to develop a scientific platform to study fatigue in Inflammatory Bowel DiseasePreprint
Hall, R., Whelan, R. J., Cartlidge, P. D., Brownson, E. F., Mowat, C., Seenan, J. P., MacDonald, J. C., Campbell, I., Chuah, C. S., & Ho, G. (2025) · medRxiv · doi:10.1101/2025.01.18.25320777 · Cited by 1
Letter: psychological remission ‐ a future endpoint in inflammatory bowel disease? Authors’ reply
Panara, A. J., Yarur, A. J., & Sussman, D. A. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12784
Overview of Oncology Drug Development
Malik, L., & Weitman, S. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_1
Das können Sie heute für CED-Patienten tun
Kucharzik, T. F. (2016) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-016-8234-9
“Einen weiteren Baustein in der Entwicklung personalisierter erapien stellt die Entwicklung neuer erapieziele dar, die sich an den Bedürfnissen und Erwartungen der Patienten orientieren (sogenannte „patient reported outcomes“) [31].”
Background
Objective Assessment of Clinical Disease Activity
Louis, E. J., Kemseke, C. V., & Reenaers, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-33703-6_23
Editorial: international consensus in clinical trial end‐points in ulcerative colitis – clarity or just a step in clearing the fog?
Christensen, B., & Sparrow, M. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14007
Disability Index as a New Outcome Measure in Patients with Inflammatory Bowel Disease
Choi, H. H., & Cho, Y. (2017) · Gut and Liver · doi:10.5009/gnl17103
“International consensus is required to develop validated PROs according to FDA criteria, and these PROs should be translated into as many languages as possible.(5) Finally, such PROs could improve the lives of patients with IBD.”
BackgroundMethodInfluential
The prevalence and impact of irritable bowel syndrome-typesymptoms and psychological co-morbidity on inflammatorybowel disease
Gracie, D. J. (2018) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Disease Modification in Crohn’s Disease
Allen, P. B., & Peyrin‐Biroulet, L. (2019) · Springer eBooks · doi:10.1007/978-3-030-11446-6_3
Treatment Evaluation in Inflammatory Bowel Diseases: a Move towards Validated Patient-Reported Outcome Measures (PROM)
Hammer, H. F. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-2432
Predictors of each quality of life dimension in Crohn’s disease patients initiating an anti-TNF treatment: differentiated effects of patient-, disease-, and treatment-related characteristics
Monmousseau, F., Mulot, L., Rüsch, E., Picon, L., Laharie, D., Fotsing, G., Gargot, D., Charpentier, C., Buisson, A., Trang, C., et al. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.2025419
Use of mHealth by Patients with Immune-Mediated Inflammatory Diseases: Cross-Sectional Survey (Preprint)Preprint
Chamorro‐de‐Vega, E., Romero-Jiménez, R. M., Escudero‐Vilaplana, V., Ais‐Larisgoitia, A., Lobato‐Matilla, E., González, C. M., Menchen, L. A., Baniandrés, O., Ibares-Frias, L., Lobo-Rodríguez, C., et al. (2022) · doi:10.2196/preprints.37445
Patient-reported Outcome Measures in Perianal Fistulizing Crohn’s Disease
Queiroz, N. S. F., Garcia, K. S., Miranda, E. F., & Kotze, P. G. (2022) · Reviews on Recent Clinical Trials · doi:10.2174/1574887117666220425125424
Faculty Opinions recommendation of Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
Satsangi, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732845043.793569708
Patient Priorities
Magro, F., & Pita, I. (2019) · Springer eBooks · doi:10.1007/978-3-319-75022-4_28
Editorial: measuring disease severity in inflammatory bowel disease—the whole is greater than the sum of its parts. Authors' reply
Swaminathan, A., Mules, T. C., & Gearry, R. B. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17126
Therapie des Morbus Crohn und der Colitis ulcerosa
Böcker, U. (2023) · Springer eBooks · doi:10.1007/978-3-662-64938-1_11
PRO Tips: First-Rate Guidance for Second-Line Therapy After Tumor Necrosis Factor-Alpha Exposure in Patients with Crohn’s Disease
Gogokhia, L., & Lukin, D. J. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07941-1
“Although both ulcerative colitis and CD have common characteristics, they have inherent symptomatic differences that can be directly reported by patients, providing significant input on morbidity and disease burden, increasingly recognized as powerful metrics of disease activity [8].”
Background
Upadacitinib (Rinvoq)
CADTH (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.856 · Cited by 1
Wasted and Unhelpful Trials
Crombie, I. (2021) · Wiley eBooks · doi:10.1002/9781394322183.ch3
Efficacy and safety of two-step acupuncture therapy for symptom relief in adults with mild to moderate ulcerative colitis: rationale and design of the TSA-UC randomised controlled trial
Chen, H., Fang, J., Liu, S., Gao, S., Shi, H., Ma, J., Shen, X., Wang, W., & Liu, Z. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094301
“It measures participants’ perceptions of changes in their condition using a 7-point scale: ‘very much improved’, ‘much improved’, ‘minimally improved’, ‘no change’, ‘minimally worse’, ‘much worse’ or ‘very much worse’.”
Integrating Patient Priorities
Maia, C., Moreira, P., Pita, I., Estevinho, M. M., & Magro, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-87503-8_42
Benchmarks after bowel resection in Crohn’s disease: implementing clinically meaningful health-related quality of life targets
Ueland, T. E., Shroder, M. M., Younan, S. A., Horst, S., McCoy, A. B., Bachmann, J. M., & Hawkins, A. T. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11983-z
“Keywords Patient-reported outcome measures · Crohn’s disease · PASS · MCID Health-related quality of life is an important therapeutic target in Crohn’s disease [1–3].”
Bedeutung von PROMs für Therapiesteuerung und Erfolgskontrolle bei der Behandlung chronisch-entzündlicher Darmerkrankungen
Schüller, A., & Howaldt, S. M. (2025) · coloproctology · doi:10.1007/s00053-025-00911-3
Invisible Burdens
Shenoy, S. M., DeBroff, J., Lacoste, J., Giselbrecht, E., Gbenebitse, N. O., Llona, R., Moran, H. R., Rozenberg, F. D., Keefer, L., & Wong, S.-Y. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002275
Advancing Clinical Trial Methodology and Reporting of Outcomes for Exclusive Enteral Nutrition and Partial Enteral Nutrition in Crohn's Disease: Challenges and Recommendations
Melton, S. L., Fitzpatrick, J. A., Chu, M. K. W., Gkikas, K., Monro, E., Matthews, J., Halmos, E. P., & Day, A. S. (2025) · JCC Plus · doi:10.1002/jcc5.70001
Successful collection of patient-reported outcomes shows improvement in quality of life, depression, and disease activity among patients with Inflammatory Bowel Disease: A real-world studyPreprint
Gu, C., Bennett, A. L., Bachmann, J. M., Schwartz, D. A., Beaulieu, D. B., Scoville, E., Dalal, R. L., Pabla, B., McCoy, A. B., Slaughter, J. C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5423345/v1
Additional file 4 of Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study
Berre, C. L., Bourreille, A., Flamant, M., Bouguen, G., Siproudhis, L., Dewitte, M., Dib, N., Cesbron-Metivier, E., Goronflot, T., Hanf, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12143946
Additional file 1 of Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study
Berre, C. L., Bourreille, A., Flamant, M., Bouguen, G., Siproudhis, L., Dewitte, M., Dib, N., Cesbron-Metivier, E., Goronflot, T., Hanf, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12143928
Additional file 3 of Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study
Berre, C. L., Bourreille, A., Flamant, M., Bouguen, G., Siproudhis, L., Dewitte, M., Dib, N., Cesbron-Metivier, E., Goronflot, T., Hanf, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12143943
Additional file 2 of Protocol of a multicentric prospective cohort study for the VALIDation of the IBD-disk instrument for assessing disability in inflammatory bowel diseases: the VALIDate study
Berre, C. L., Bourreille, A., Flamant, M., Bouguen, G., Siproudhis, L., Dewitte, M., Dib, N., Cesbron-Metivier, E., Goronflot, T., Hanf, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12143937
Immigrant Status and Work Productivity Loss in Inflammatory Bowel Disease: A Prospective Cohort StudyPreprint
Sheka, D. T., Chong, D., Bharatselvam, S., Yang, J. X., Sasson, A. N., Cino, M., & Tandon, P. (2026) · Research Square · doi:10.21203/rs.3.rs-8990302/v1
Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study
Loftus, E. V., Joshi, N., Sands, B. E., Jairath, V., Blumenstein, I., Shukla, N., Kligys, K. R., Anschutz, T., Griffith, J. M., Zambrano, J., et al. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004044
A stromal-state dichotomy governs recalcitrance or remission in inflammatory bowel diseasePreprint
Tindle, C., Penrose, H. M., Sinha, S., Mullick, M., Carpio-Perkins, K., Hayashi, M., Carpinelli, S., McLaren, E., Hsieh, C.-C., Zablan, K. M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.01.720931
Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece
Tzanetakos, C., Vakouftsi, V. R., Mavridoglou, G., Angelopoulou, A., & Gourzoulidis, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1866461
Health‐Related Quality of Life Following Botulinum Toxin for Retrograde Cricopharyngeus Dysfunction
Munshi, M., Senthil, N., Lerner, B. A., & Lerner, M. Z. (2026) · The Laryngoscope · doi:10.1002/lary.70807
Rethinking clinical response criteria in trials of chronic enteropathy in dogs: what change is truly meaningful?
Méric, T., Verollet, C., Darnis, É., Rhimi, M., & Hernandez, J. L. (2026) · Journal of Veterinary Internal Medicine · doi:10.1093/jvimsj/aalag164
Digital patient-reported outcomes to evaluate treatment response to filgotinib in patients with ulcerative colitis
Mazza, L., Matini, L., Dunbar, G., Sharda, A. P., White, L., Kormilitzin, A., Azzu, H., Cripps, S., Sanford, J., Cheung, V., et al. (2026) · Patient Related Outcome Measures · doi:10.1080/1179271x.2026.2740952
The Evaluation, Diagnosis, and Treatment of Inflammatory Bowel Diseases over the Past 100 Years: A Brief Review
Scott, F. I., & Lichtenstein, G. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-11077-6_1

Authors: Williet, N., Sandborn, W. J., & Peyrin–Biroulet, L.
Affiliations: Inserm (FR)
University of California San Diego (US)
ORCID: Williet, Nicolas
Sandborn, William J.
Venue: Clinical Gastroenterology and Hepatology
Publisher: Elsevier BV
Published: 2014-08
Volume: 12
Issue: 8
Pages: 1246-1256.e6
ISSN: 1542-3565 (ISSN-L)
DOI: 10.1016/j.cgh.2014.02.016
OpenAlex: W2033081617
Cited by: 260
References: 150
Citations by year: 2026: 9 · 2025: 19 · 2024: 16 · 2023: 14 · 2022: 21 · 2021: 19 · 2020: 26 · 2019: 18 · 2018: 30 · 2017: 24 · 2016: 33 · 2015: 22 · 2014: 8
FWCI: 3.83
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Clinical Gastroenterology and Hepatology (publishedVersion)
PubMed (publishedVersion)
HAL (submittedVersion)
Funders: Optimer Pharmaceuticals
Boehringer Ingelheim
Shire
Bristol-Myers Squibb
Pfizer
Orexigen Therapeutics
UCB Pharma
Novartis
Roche
Gilead Sciences
Genentech
Merck
Topics: Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
Keywords: patient-reported outcomes, inflammatory bowel disease, Crohn's disease, primary endpoint, clinical trial endpoints, CDAI, quality of life, fatigue, anxiety and depression, labor productivity, disability, IBDQ, Short Form-36
MeSH terms: Humans, Surveys and Questionnaires, Inflammatory Bowel Diseases, Treatment Outcome, Drug Monitoring, Patient Satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks